ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SEER / insiders
QTRX (22) HBIO (47) RPID (34) LAB (27) ⌘ Pro Terminal β†’

Seer Inc. (Class A) (SEER) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.68 -13.40% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.64

Seer Inc. (Class A) (SEER) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $93.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SEER Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SEER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Seer Inc. (Class A) (NASDAQ: SEER) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.68 (-13.40% 1D, market cap $93.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SEER ranks #910 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SEER compare to QTRX and HBIO in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), SEER carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 51.1%, and ROIC of -29.1%. By comparison, QTRX (Quanterix Corporation) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $137.4M) and HBIO (Harvard Bioscience Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $40.5M). Among the 5-stock peer group, SEER leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SEER?
β–Ό

Per SEER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001726445), Seer Inc. (Class A) generated $16.6M in revenue (+17.0% YoY), -$73.6M in net income, and -$46.2M in free cash flow against $296.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.64 (-2.60%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (26/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510026
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D-
Cash (3)Whales (3)SEC (8)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-14.3% Base Target
$3 Bull$1 Base$1 Bear
πŸ“¬ FREE SEER RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SEER)Realized 20D OHLCV Swing Band: Β±11.3%
Deterministic 5-Pillar Attribution (26/100 Composite)
πŸ” WHY SEER SCORES 26/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Macro Regime Fit+7/20 pts (27% of score)

FRED Regime Γ— Technicals: 16% of 52W Range β€’ RSI-14 at 36.4 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
34
Grade E$2.11-6.2% Next Q
Q2 (-2Q)
31
Grade E$1.98-1% Next Q
Q3 (-1Q)
29
Grade E$1.96-14.3% Next Q
Current
26
Grade E$1.68-10.5% Hist 90D Ξ±
Trajectory: E (34) β†’ E (26)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SEER Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SEER currently carries a cautious 26/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.00) and Max Pain ($1.76) forces dealer call-delta covering toward $2.50.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SEERβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSEER Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

SEER Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SEER)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SEER. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SEER)

  • βœ“Walkthrough of SEER's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SEER // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.85%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $1.94H $1.94L $1.68C $1.68VOL 516.5K
RES: $2.44SUP: $1.61SMA50: $2.00SMA200: $1.92
$2.44$2.20$1.96$1.72$1.48RES $2.44SUP $1.61$1.682026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SEER Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SEER Butterfly Map β†’ + Track SEER β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +17.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SEER today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SEER. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SEER today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SEER)

Health Care Rank #910 of 1015 βš”οΈ QTRX vs SEER Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SEER vs. QTRX, HBIO, RPID, LAB)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Seer Inc. (Class A) (SEER) ranks #910 by composite RQD confidence (26/100, grade E) and #663 by equity capitalization ($93.0M). Within this direct 5-issuer industry benchmark cohort, SEER leads on earnings valuation at N/A trailing P/E, while LAB leads on capital efficiency and profitability with -28.7% ROIC and 49.9% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SEER at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SEER ACTIVE
Seer Inc. (Class A)
E 26/100 β€” 51.1% -29.1% -13.40% $93.0M Benchmark Subject
QTRX
Quanterix Corporation
E 22/100 β€” 46.8% -35.0% -7.63% $137.4M /qtrx-vs-seer β†’
HBIO
Harvard Bioscience Inc.
D 47/100 β€” 57.7% -35.0% +1.14% $40.5M /hbio-vs-seer β†’
RPID
Rapid Micro Biosystems Inc. (Class A)
E 34/100 β€” β€” -35.0% -6.73% $36.9M /rpid-vs-seer β†’
LAB
Standard BioTools Inc.
E 27/100 β€” 49.9% -28.7% -1.61% $240.7M /lab-vs-seer β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001726445 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seer Inc. (Class A) (SEER) reported GAAP revenue of $16.6M (+17.0% vs. FY2024 revenue of $14.2M , and -0.5% cumulative change since FY2023) , GAAP net income of -$73.6M, operating cash flow of -$44.4M, and free cash flow of -$46.2M (+6.9% YoY). On the balance sheet, SEER closed FY2025 with $296.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $16.6M -$73.6M -$44.4M -$46.2M $296.1M β€”
FY2024 (FY) 2024-12-31 $14.2M -$86.6M -$46.1M -$49.7M $366.6M β€”
FY2023 (FY) 2023-12-31 $16.7M -$86.3M -$59.1M -$59.1M β€” β€”

3. SEER Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SEER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Seer Inc. (Class A) (NASDAQ: SEER) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.68 (-13.40% 1D, market cap $93.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SEER ranks #910 in composite RQD confidence.

How does SEER compare to QTRX and HBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), SEER carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 51.1%, and ROIC of -29.1%. By comparison, QTRX (Quanterix Corporation) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $137.4M) and HBIO (Harvard Bioscience Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $40.5M). Among the 5-stock peer group, SEER leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SEER?

Per SEER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001726445), Seer Inc. (Class A) generated $16.6M in revenue (+17.0% YoY), -$73.6M in net income, and -$46.2M in free cash flow against $296.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SEER trading relative to its 50-day, 200-day, and 52-week technical levels?

SEER last traded at $1.68 (-13.40% on volume of 516,545 shares), positioning the stock -16.00% below its 50-day simple moving average ($2.00) and -12.50% below its 200-day simple moving average ($1.92). Across its 52-week range of $1.55 to $2.38, SEER sits at the 15.7% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.3% ($1.49 to $1.87).

Direct Sub-Reports: SEER RQD Cockpit SEER 12M Forecast SEER Earnings & Move SEER Dividends & DRIP SEER Insiders & 13F SEER Whale Options SEER Profit Sankey SEER News & Why
ROARABLE RATING BRIEF β€’ RQD 26/100 (E) βœ“ SEC XBRL & RQD VERIFIED

SEER β€” Seer Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Seer Inc. (Class A) (SEER) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.68 (-13.40% 1D, market capitalization $93.0M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -29.1%, gross margin of 51.1%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Seer Inc. (Class A) (SEER) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. The company reported revenue of $16.6M for FY 2025, $14.2M for FY 2024, and $16.7M for FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Seer Inc. (Class A) (SEER) reported $16.6M in annual revenue (up from $14.2M in FY2024, +17.0% YoY) and -$73.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($16.7M revenue, -$86.3M net income) through FY2025, SEER scaled operating cash flow to -$44.4M and free cash flow to -$46.2M, backed by $296.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.55 – $2.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Laboratory Analytical Instruments (Health Care), SEER carries a macro regime beta of 1.00 and gross margin of 51.1%.

  • Key Question #1: Can SEER sustain or expand its -60.0% operating margin and -29.1% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $16.6M and free cash flow of -$46.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SEER's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SEER Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Seer Inc. (Class A) (SEER) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SEER Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SEER Bull vs. Bear Conversation Board β€” What's Your Call at $1.68?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SEER 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SEER:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER β€’ Price Action & Volume Trader πŸ‚ BULLISH 🎯 Target: $2.22 (+32.1%)
πŸ“Œ Pinned Debate

The company reported cash of $47.3M for FY 2025 and its operating loss narrowed from -$103.5M in FY 2023 to -$78.0M in FY 2025.

Long SEER at $1.68 targeting $2.22. The company reported cash of $47.3M for FY 2025 and its operating loss narrowed from -$103.5M in FY 2023 to -$78.0M in FY 2025.. Institutional whale score is 3/20 and the risk/reward vs. the $1.55 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 πŸ‚ BULL

@TapeReader_Pro Agree on the RQD 26/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.68 and keeping dry powder in case we test $1.56.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.39 (-17.3%)
Spot @ $1.68

The company's operating and net margins are both -60%, ROIC is -29.1%, and the Altman Z-Score is 0.2.

Fading this rally in SEER at $1.68. The company's operating and net margins are both -60%, ROIC is -29.1%, and the Altman Z-Score is 0.2.. With a beta of 1.0 and the stock sitting at $1.68 (52-wk range $1.55–$2.38), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%